NEW YORK, Sept. 16, 2016 -- Barrack, Rodos & Bacine is investigating the Board of Directors of Standex International Corp. (“Standex” or the “Company”) for possible violations of securities laws and Delaware law relating to the Proxy Statement the Company filed concerning the upcoming annual shareholder meeting to be held on October 27, 2016.
The Proxy Statement filed by Standex with the U.S. Securities and Exchange Commission on September 9, 2016 recommends that Standex shareholders vote to approve five Company proposals. Barrack, Rodos & Bacine’s investigation of these Company proposals indicates that they may contain misleading information that will inhibit a meaningful stockholder vote.
Holders of Standex stock are encouraged to contact Michael Toomey of Barrack Rodos & Bacine, at the following toll-free number: 877-386-3304, or via e-mail to [email protected].
Barrack Rodos & Bacine has more than three decades of experience prosecuting securities and corporation law actions, and has achieved some of the largest recoveries in the history of such litigation.
Michael Toomey 877-386-3304 [email protected]


Apple Turns 50: From Garage Startup to AI Crossroads
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 



